Plerixafor 24mg is supplied in ready-to-use vials, and should be administered as a subcutaneous injection over the abdominal area. In case the needed volume exceeds 1.2mL, the dose can be split and should be given in 2 injections. Patients should be observed by nursing staff for an hour following each celrixafor dose with blood pressure and pulse monitored every 15 minutes. In an event of drug overdose/missed dose, inform your healthcare practitioner as soon as possible.
Most common adverse reactions include nausea, diarrhea, injection site reactions, fatigue, headache, artralgia, vomiting, and dizziness.
- The plerixafor injection 20 mg/ml is not intended for the HSC mobilization and harvest in patients with leukemia. Patients should be monitored for the white blood cell counts during the use of this medication.
- All patients with this drug should be monitored for the platelet counts. Women of childbearng potential are advised to avoid conceiving a baby while receiving treatment with plerixafor injection 24 mg/1.2 ml.
- Nursing mothers are advised to discuss with their healthcare provider prior to starting breastfeeding.
- Advise patients about the signs and symptoms of the potential systemic reactions such as periorbital swelling, urticaria, dyspnea, or hypoxia while and after this injection. Instruct patients to contact healthcare practitioners immediately in case they have left upper abdominal pain or shoulder pain.
- Inform patients that the celrixafor may be responsible for causing the gastrointestinal disorders, including nausea, diarrhea, vomiting, abdominal pain, and flatulence.
Care should be exercised in the handling of Celrixafor. Celrixafor injections should not be opened or crushed. Store the vials at temp. 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F).
WHAT IS PLERIXAFOR AND WHAT IT IS USED FOR:
Plerixafor specifically is a hematopoietic stem cell mobilizer indicated together with G-CSF in order to mobilize the hematopoietic stem cells to the peripheral blood for the collection and subsequent autologous transplantation in patients with NHL or MM.